Skip to content
Download PDF

Desensitization

Part 11: Immune-Mediated, Inflammatory, and Rheumatologic Disorders · Part 11 – Rheumatology & Immunology · Chapter 365

Key Clinical Points

  1. Drug desensitization (DD) is a temporary immunotherapy modality using multistep protocols to safely reintroduce drugs causing acute or delayed reactions.
  2. Tryptase levels > 11.4 ng/mL or > 1.6x baseline within 30 min to 4 h are diagnostic of type I and mixed reactions.
  3. Desensitization is indicated for Type I (IgE-dependent/independent), CRR, Mixed, and nonsevere delayed Type IV; it is contraindicated for SCARS (SJS, TEN, DRESS, AGEP).
  4. Standard 3-bag protocol: three bags (1/100, 1/10, undiluted) with 12 doubling steps every 15 min, reaching target dose in 5.7 h.
  5. Breakthrough reactions (BTRs) occur in 10–30% of protocols; they are typically mild and do not preclude completion in 99% of cases.
  6. Hereditary alpha tryptasemia (HαT) is a common trait (4–6% of Caucasians) where baseline tryptase ≥ 7.5 ng/mL may be present.
  7. Kounis syndrome and Takotsubo cardiomyopathy resulting from anaphylaxis are absolute contraindications for DD.
  8. Omalizumab (anti-IgE) can serve as an adjuvant in highly sensitized patients with severe IgE-mediated reactions.
  9. Early introduction of peanut protein (4–11 months) prevents ≥ 80% of peanut allergies in high-risk infants.
  10. Venom immunotherapy (VIT) for Hymenoptera requires a maintenance dose equivalent to 2–5 stings for 3–5 years (lifelong if severe).

DEFINITION & OVERVIEW

• Definition (Harrison's 22e): Drug desensitization (DD) is a temporary immunotherapy modality, delivered through multistep protocols to safely and timely reintroduce a drug that has induced an acute or delayed allergic reaction. • Core Concept: ◦ Desensitization elicits a temporary state of tolerance in sensitized patients. ◦ It utilizes immune inhibitory mechanisms (e.g., recruiting phosphatases to IgE receptors to block signal transduction). ◦ Not a permanent cure: Must be repeated for each exposure or if a pause ≥ two half-lives occurs.

Mechanism of Action

• IgE-mediated: ◦ Utilizes inhibitory mast cell/basophil pathways activated by low doses. ◦ Rapid delivery recruits phosphatases to IgE receptors → blocks signal transduction → prevents mediator release. • Non-IgE mediated: ◦ Applicable for CRRs, certain chemotherapy drugs (e.g., paclitaxel), and NSAIDs.

EPIDEMIOLOGY

• Risk Factors: Female gender, specific HLA haplotypes, atopy, polypharmacy, older age, and chronic diseases. • Peanut Allergy Trends: ◦ Sharp rise in prevalence since late 1990s in Western diets where introduction ≥ 3 years. ◦ Early introduction (4–11 months) prevents ≥ 80% of cases even if IgE sensitization is present. ◦ ~80% of children with peanut allergy remain sensitive for life.

Prevention and Avoidance

• Desensitization Efficacy: ◦ Temporary tolerance achieved through serial administration of escalating doses. ◦ Desensitized state maintained as long as drug is administered at regular intervals based on half-life.

ETIOLOGY & PATHOPHYSIOLOGY

• Reaction Timing: ◦ Acute/Immediate: During or within 1–6 h. ◦ Delayed: 6 h to several days/weeks. • Severity Grading: ◦ Grade 1 (Mild): One organ affected. ◦ Grade 2 (Moderate): Two or more organs. ◦ Grade 3 (Severe): Changes in vital signs. • Phenotypes & Endotypes: ◦ Type I: IgE-dependent/independent; involves mast cells, histamine, and tryptase. ◦ CRR: T-cell activation; associated with IL-6 elevation. ◦ Mixed: Combination of Type I and CRR symptoms. ◦ Type II/III: Antibody-mediated or immune complex-mediated (Contraindicated for DD). ◦ Type IV: Delayed maculopapular rash (Indicated if benign). • SCARS (Type IV Severe Cutaneous Adverse Reactions): ◦ DRESS: 2–8 week delay; eosinophilia, atypical lymphocytosis. ◦ SJS-TEN: 4–28 day delay; epidermal necrosis, mucosal involvement. ◦ AGEP: 24–48 hour delay; sterile pustules, neutrophilic leukocytosis. ◦ Note: SCARS are absolute contraindications for DD due to risk of severe reaction from minute amounts.

Table 1: Drug Allergy Phenotypes, Endotypes, and Biomarkers

• Type I/Mixed: Tryptase elevated (>11.4 ng/mL or >1.6x baseline) → Desensitization Indicated. • CRR: IL-6 elevated (e.g., >3000 pg/mL) → Desensitization Indicated. • Type IV (Benign): Maculopapular rash → Desensitization Indicated. • SCARS: DRESS, SJS-TEN, AGEP → Not Indicated, Avoid Medication.

Table 2: Type IV Severe Cutaneous Adverse Reactions (SCARs)

• DRESS: 2–8 week delay; eosinophilia/atypical lymphocytosis. • SJS-TEN: 4–28 day delay; epidermal necrosis, mucosal involvement. • AGEP: 24–48 hour delay; sterile pustules, neutrophilic leukocytosis.

CLINICAL FEATURES

• Type I Indicators: ◦ Symptoms: Flushing, pruritus, urticaria, bronchospasm, hypotension. ◦ Tryptase: >11.4 ng/mL or >1.6x baseline (within 30 min to 4 h) → Diagnostic of Type I/Mixed. • CRR Indicators: ◦ Symptoms: Fever, chills, pain, tachycardia. ◦ IL-6: Transient serum elevation. • Hereditary Alpha Tryptasemia (HαT): ◦ Autosomal dominant; 4–6% of Caucasians. ◦ Baseline tryptase ≥ 7.5 ng/mL may indicate HαT.

Clinical Vignettes

• Rituximab Case: Grade 2 Mixed reaction; Tryptase 52 ng/mL (Normal 11.4); successfully desensitized via 3-bag protocol. • Carboplatin Case: Grade 3 Type I reaction; IL-6 >3000 pg/mL (Normal <17.4 pg/mL, Baseline <2.9 pg/mL); successfully desensitized.

DIFFERENTIAL DIAGNOSIS

• Key Distinctions: ◦ Type I vs. CRR: Tryptase (Type I) vs. IL-6 (CRR). ◦ Benign Type IV vs. SCARS: Desensitization possible for benign; strictly contraindicated for SCARS. • Contraindications for DD: ◦ SCARS (SJS, TEN, DRESS, AGEP). ◦ Type II/III reactions. ◦ Vasculitis. ◦ Kounis syndrome and Takotsubo cardiomyopathy.

Diagnostic Clues

• Tryptase: >11.4 ng/mL or >1.6x baseline (30m–4h) indicates Type I/Mixed. • IL-6: Transient elevation associated with CRR. • Skin Testing (ST): Positive result indicates IgE-mediated reaction. • Basophil Activation Test (BAT): Evidence of IgE sensitization without direct ST risk.

INVESTIGATIONS & DIAGNOSIS

  1. Skin Testing (ST): ◦ Limitations: Time since reaction, severity of reaction, availability of components. ◦ Utility: Identifies IgE-mediated reactions; however, anaphylactic reactions can lead to false negatives due to mediator depletion.
  2. Basophil Activation Test (BAT): ◦ Provides evidence of IgE sensitization by challenging basophils in vitro. ◦ Advantage: Eliminates need for direct ST in high-risk patients.
  3. Serum Analysis: ◦ Tryptase measurement to distinguish Type I/Mixed from other reactions. ◦ IL-6 measurement to identify CRR.

Diagnostic Algorithm

  1. Clinical Assessment: Evaluate history of anaphylaxis and necessity of drug.
  2. Biomarker Screening: Assess Tryptase (Type I) and IL-6 (CRR).
  3. Sensitivity Testing: Perform ST or BAT to confirm IgE status.
  4. Risk Stratification: Identify contraindications (SCARS, Type II/III, Kounis).

MANAGEMENT & TREATMENT

  1. Premedication Regimen: ◦ Certirizine 10 mg ◦ Aspirin 325 mg ◦ Famotidine 20 mg ◦ Montelukast 10 mg ◦ Methylprednisolone 40 mg ◦ Acetaminophen 650 mg
  2. Desensitization Protocols: ◦ 3-bag, 12-step: 1/100, 1/10, and undiluted bags; 12 doubling steps every 15 min → Target reached in 5.7 h. ◦ 4-bag, 16-step: Used for severe initial reactions or comorbidities. ◦ 1-bag, 4-step: Recent use; mixed outcomes (higher epinephrine use).
  3. Breakthrough Reactions (BTRs): ◦ Occurrence: 10–30% of protocols. ◦ Management: Symptom-specific; include epinephrine for severe reactions. ◦ Outcome: Do not preclude completion in 99% of cases.
  4. Adjuvant Therapy: ◦ Omalizumab: Used for highly sensitized patients with severe IgE-mediated reactions.

Table 3: Principles of Drug Desensitization

• Indications: Type I, CRR, Mixed, Type IV. • Contraindications: SCARS, Organ-specific toxicity, Cytopenias, Serum sickness, Kounis/Takotsubo. • Risk Factors: β-blockers, ACE inhibitors, Atopy, HLA genotypes, Female sex, Polypharmacy, Advanced age.

PROGNOSIS & COMPLICATIONS

• BTR Management: ◦ Symptoms typically mild. ◦ Treatment: Symptom-specific (e.g., epinephrine for severe). • Efficacy of DD: ◦ Equivalence to standard administration in terms of infection clearance and clinical response. • Venom Immunotherapy (VIT): ◦ Indicated for Hymenoptera anaphylaxis if IgE confirmed. ◦ Maintenance: Equivalent to 2–5 stings. ◦ Duration: 3–5 years; lifelong for severe respiratory/cardiovascular cases or mastocytosis.

KEY PEARLS & CLINICAL TRAPS

• Tryptase Threshold: >11.4 ng/mL (or 1.6x baseline) is the definitive marker for Type I/Mixed reactions. • SCARS Exclusion: SJS, TEN, DRESS, and AGEP are absolute contraindications for desensitization. • HαT Awareness: Patients with baseline tryptase ≥ 7.5 ng/mL may have a genetic predisposition (HαT). • BTR Frequency: 10–30% of patients experience BTRs, but these rarely lead to treatment discontinuation. • Desensitization Nature: It is a temporary state; it does not provide long-term immunity and must be repeated for each exposure. • Peanut Prevention: Early introduction (4–11 months) is highly effective in preventing peanut allergy.